We analyzed variations of CCL25 expression in tumor samples from patients with melanoma treated with anti–PD-1 and showed that sustained CCL25 expression during ICB characterized patients responding versus nonresponding to the therapy. The gene discussed is CCL25; the disease is neoplasm.